Kwality Pharmaceuticals Limited (BOM:539997)
India · Delayed Price · Currency is INR 3,590.75
+146.00 (4.24%)
At close: Aug 17, 2026
Kwality Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 5,540 | 5,031 | 3,702 | 3,072 | 2,510 | 4,562 |
Other Revenue | -0 | -0 | - | - | - | - |
| 5,540 | 5,031 | 3,702 | 3,072 | 2,510 | 4,562 | |
Revenue Growth | 37.94% | 35.90% | 20.52% | 22.36% | -44.97% | 73.42% |
Cost of Revenue | 2,954 | 2,660 | 1,882 | 1,580 | 1,136 | 2,051 |
Gross Profit | 2,586 | 2,371 | 1,820 | 1,492 | 1,375 | 2,511 |
Selling, General & Admin | 598.77 | 572.88 | 454.65 | 326.29 | 301.26 | 202.76 |
Other Operating Expenses | 613.47 | 595.44 | 544.8 | 485.2 | 456.86 | 573.94 |
Operating Expenses | 1,413 | 1,366 | 1,182 | 1,007 | 907.71 | 883.61 |
Operating Income | 1,173 | 1,005 | 637.51 | 484.53 | 466.8 | 1,627 |
Interest Expense | -108.71 | -109.7 | -98.78 | -103.87 | -60.2 | -29.17 |
Interest & Investment Income | 1.25 | 1.25 | 1.62 | 1.3 | 1.23 | 1.23 |
Currency Exchange Gain (Loss) | - | - | 0.77 | - | 12.66 | 16.62 |
Other Non Operating Income (Expenses) | 0 | 0 | -0 | - | -0 | -0 |
EBT Excluding Unusual Items | 1,066 | 896.09 | 541.12 | 381.96 | 420.48 | 1,616 |
Gain (Loss) on Sale of Assets | 7.12 | 7.12 | 0.28 | 0.02 | 0.54 | - |
Asset Writedown | - | - | - | - | -70.51 | - |
Other Unusual Items | -8.29 | -8.29 | - | -70.99 | -94.78 | - |
Pretax Income | 1,065 | 894.92 | 541.4 | 310.99 | 255.72 | 1,616 |
Income Tax Expense | 254.03 | 221.46 | 143.37 | 74.83 | 62.93 | 416.28 |
Earnings From Continuing Operations | 810.49 | 673.46 | 398.03 | 236.16 | 192.8 | 1,199 |
Minority Interest in Earnings | -0.04 | 0 | 0.42 | 1.8 | 0.93 | 0.53 |
Net Income | 810.45 | 673.46 | 398.45 | 237.96 | 193.72 | 1,200 |
Net Income to Common | 810.45 | 673.46 | 398.45 | 237.96 | 193.72 | 1,200 |
Net Income Growth | 86.68% | 69.02% | 67.44% | 22.84% | -83.86% | 692.24% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Change | -0.07% | - | - | - | - | 0.00% |
EPS (Basic) | 78.11 | 64.90 | 38.40 | 22.93 | 18.67 | 115.64 |
EPS (Diluted) | 78.10 | 64.90 | 38.36 | 22.93 | 18.67 | 115.64 |
EPS Growth | 86.80% | 69.19% | 67.27% | 22.84% | -83.86% | 692.22% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -280.15 | 294.25 | 131.42 | -62.92 | 54.45 |
Free Cash Flow Per Share | - | -27.00 | 28.36 | 12.66 | -6.06 | 5.25 |
Gross Margin | 46.68% | 47.13% | 49.16% | 48.56% | 54.75% | 55.04% |
Operating Margin | 21.18% | 19.97% | 17.22% | 15.77% | 18.59% | 35.66% |
Profit Margin | 14.63% | 13.39% | 10.76% | 7.75% | 7.72% | 26.30% |
Free Cash Flow Margin | - | -5.57% | 7.95% | 4.28% | -2.51% | 1.19% |
EBITDA | 1,375 | 1,203 | 820.4 | 680.12 | 616.38 | 1,734 |
EBITDA Margin | 24.82% | 23.91% | 22.16% | 22.14% | 24.55% | 38.01% |
D&A For EBITDA | 201.91 | 198.1 | 182.9 | 195.59 | 149.58 | 106.91 |
EBIT | 1,173 | 1,005 | 637.51 | 484.53 | 466.8 | 1,627 |
EBIT Margin | 21.18% | 19.97% | 17.22% | 15.77% | 18.59% | 35.66% |
Effective Tax Rate | 23.86% | 24.75% | 26.48% | 24.06% | 24.61% | 25.77% |
Revenue as Reported | 5,571 | 5,059 | 3,721 | 3,090 | 2,540 | 4,597 |
Advertising Expenses | - | 32.45 | 16.81 | 0.66 | 1.67 | 1.25 |